Article Sidebar

Submitted
4 November 2016
Accepted
4 November 2016
Published
15 November 2016
Download
PDF
Statistic
Read Counter : 967 Download : 1151

Main Article Content

Abstract

Hydroxyethyl starch (HES) is a colloid administered frequently for intravascular volume expansion during perioperative period. Impairment of haemostasis have been reported during HES administration, but the volume of solution administered was usually higher than 20 ml.kg-1. The objective of this study was to evaluate the effect of Hydroxyethyl starch 200/0.5 dose less than 20 ml.kg-1 on von Willebrand factor serum level and activated partial thromboplastin time. A prospective, observational study was conducted to evaluate von Willebrand factor and activated partial thromboplastin time of patients receiving Hydroxyethyl starch 200/0.5. Inclusion criteria were patients undergoing elective surgery who were going to receive Hydroxyethyl starch 200/0.5 intraoperatively. Fourty six patients were divided into patients receiving crystalloid only group (n=23 patients) and hydroxyethyl starch (n=23 patients). Coagulation variables were assesed 30 minute after insicion and 60 minute after infusion of crystalloid or colloid. Measurement of von Willebrand within each group after crystalloid or HES 200 infusion showed significant decrease, from (mean±SE) 97.688±15.219 ng/ml to 31.611±10.058 ng/ml (p< 0.001) in crystalloid group and 92.884±15.208 ng/ml to 27.378±6.399 ng/ml (p<0.001) in HES 200 group. Activated partial thromboplastin time change was statistically significant (mean±SE) 31.27±1.39 to 35.61±1.62 in HES group only (p=0.007), but this change was not clinically significant. In conclusion, there was neither significant difference in von Willebrand serum level nor in activated partial thromboplastin time between the two groups. There was no coagulation influence with clinically significant effect in the use of HES 20 ml/kg BW in patients undergoing elective surgery.

Keywords

hydroxyethyl starch 200/0.5 coagulation impairment von Willebrand factor serum level activated partial thrombopalstin time

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Atmaja, S. P., Khotib, J., Rahardjo, E., Shinta, D. W., Rahmadi, M., & Suprapti, B. (2016). EFFECT OF HYDROXYETHYL STARCH 200/0.5 ON VON WILLEBRAND FACTOR SERUM LEVEL AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT). Folia Medica Indonesiana, 51(4), 221–227. https://doi.org/10.20473/fmi.v51i4.2848
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Boldt J (2008). Fluid choice for resuscitation in trauma. International Trauma Care 18, 57-65
  2. Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV (2013). Clearance of von Willebrand factor. J Thromb Haemost 11 Suppl 1, 202-211
  3. Collis RE, Collins PW, Gutteridge CN, Kaul A, Newland AC, Williams DM, Webb AR (1994). The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation; an in vitro study. Intensive Care Med 20, 37-41
  4. de Jonge E, Levi M, Büller HR, Berends F, Kesecioglu J (2001). Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med 27, 1825-1829
  5. Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tí¸nnesen E, Ingerslev J, Sí¸rensen B (2009). Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 7, 795-802
  6. Gabali A, Jazearly T, Ramchandren R, Bluth MH (2014). Applications of coagulation testing and methodology in the trauma patient. Research and Reviews: Journal of Medical and Health Sciences 3, 1-4
  7. Gan TJ (2011). Colloid or crystalloid: any differences in outcomes? IARS Review Course Lectures, 7-12
  8. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H (2012). Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 16, R94
  9. Innerhofer P, Fries D, Margreiter J, Klingler A, Kühbacher G, Wachter B, Oswald E, Salner E, Frischhut B, Schobersberger W (2002). The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 95, 858-865
  10. Kamal AH, Tefferi A, Pruthi RK (2007). How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 82, 864-873
  11. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P (2008). The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 107, 382-390
  12. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P (2001). Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 92, 855-862
  13. Lenting PJ, Christophe OD, Denis CV (2015). von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 125, 2019-2028
  14. Mills GH (2007). Hydroxyethyl starch: does our choice of colloid prevent or add to renal impairment? Br J Anaesth 98, 157-159
  15. Muralidhar K, Garg R, Mohanty S, Banakal S (2010). Influence of colloid infusion on coagulation during off-pump coronary artery bypass grafting. Indian J Anaesth 54, 147-153
  16. Myburgh JA and Mythen MG (2013). Resuscitation fluids. The New England Journal of Medicine 369, 1243–1251
  17. Ng KF, Lam CC, Chan LC (2002). In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial. Br J Anaesth 88, 475-480
  18. Peyvandi F, Garagiola I, Baronciani L (2011). Role of von Willebrand factor in the haemostasis. Blood Transfus 9, s3-s8
  19. Reininger AJ (2008). Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia 14, 11–26
  20. Rittoo D, Gosling P, Simms MH, Smith SR, Vohra RK (2005). The effects of hydroxyethyl starch compared with gelofusine on activated endothelium and the systemic inflammatory response following aortic aneurysm repair. Eur J Vasc Endovasc Surg 30, 520-524
  21. Ruttmann TG, James MF, Finlayson J (2002). Effects on coagulation of intravenous crystalloid or colloid in patients undergoing peripheral vascular surgery. Br J Anaesth 89, 226-230
  22. Sadler JE (2009). Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program, 106–112
  23. Wilson DD (2007). McGraw-Hill Manual of Laboratory and Diagnostic Tests 1st Edition, New York, McGraw-Hill Education

Most read articles by the same author(s)